1. Teschke R, Brand A, Strohmeyer G. Induction of hepatic microsomal gamma-glutamyltransferase activity following chronic alcohol consumption. Biochem Biophys Res Commun 1977;75:718-724.
[CROSSREF] [PUBMED]
2. Sharpe PC, McBride R, Archbold GP. Biochemical markers of alcohol abuse. QJM 1996;89:137-144.
[CROSSREF] [PUBMED] [PDF]
3. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004;89:5410-5414.
[CROSSREF] [PUBMED]
4. Kim DJ, Noh JH, Cho NH, Lee BW, Choi YH, Jung JH, et al. Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med 2005;22:1134-1140.
[CROSSREF] [PUBMED]
5. Ndrepepa G, Braun S, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, et al. Relation of gamma-glutamyl transferase to cardiovascular events in patients with acute coronary syndromes. Am J Cardiol 2016;117:1427-1432.
[CROSSREF] [PUBMED]
6. Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, et al. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism 2016;65:783-793.
[CROSSREF] [PUBMED]
7. Lee MY, Koh SB, Koh JH, Nam SM, Shin JY, Shin YG, et al. Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. Diabet Med 2008;25:469-475.
[CROSSREF] [PUBMED]
8. Andre P, Balkau B, Vol S, Charles MA, Eschwege E. DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007;30:2355-2361.
[CROSSREF] [PUBMED]
9. Yadav D, Lee MY, Kim JY, Ryu H, Huh JH, Bae KS, et al. Combined effect of initial and longitudinal increases in γ-glutamyltransferase on incident metabolic syndrome: ARIRANG Study. Yonsei Med J 2017;58:763-769.
[CROSSREF] [PUBMED] [PMC]
10. Bo S, Gambino R, Durazzo M, Guidi S, Tiozzo E, Ghione F, et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol 2005;11:7109-7117.
[CROSSREF] [PUBMED] [PMC]
11. Lafontan M, Viguerie N. Role of adipokines in the control of energy metabolism: focus on adiponectin. Curr Opin Pharmacol 2006;6:580-585.
[CROSSREF] [PUBMED]
12. Lee MY, Weon CS, Ko CH, Lee BJ, Lee Y, Kim MJ, et al. Relations between serum gamma-glutamyltransferase and prevalence of diabetes mellitus. Korean J Med 2004;67:498-505.
13. Kim Y, Han BG. KoGES group. Cohort profile: the Korean Genome and Epidemiology Study (KoGES) consortium. Int J Epidemiol 2017;46:e20.
[CROSSREF] [PUBMED] [PDF]
14. Kim J, Kim Y, Ahn YO, Paik HY, Ahn Y, Tokudome Y, et al. Development of a food frequency questionnaire in Koreans. Asia Pac J Clin Nutr 2003;12:243-250.
[PUBMED]
15. Ahn Y, Kwon E, Shim JE, Park MK, Joo Y, Kimm K, et al. Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur J Clin Nutr 2007;61:1435-1441.
[CROSSREF] [PUBMED] [PDF]
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
[CROSSREF] [PUBMED]
17. American Heart Association. National Heart, Lung, and Blood Institue. Grundy SM, Cleeman JI, Daniels SR, Donato KA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322-327.
[CROSSREF] [PUBMED]
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
[CROSSREF] [PUBMED]
19. Yoon YS, Oh SW. Optimal waist circumference cutoff values for the diagnosis of abdominal obesity in Korean adults. Endocrinol Metab (Seoul) 2014;29:418-426.
[CROSSREF] [PUBMED] [PMC]
20. Breitling LP, Raum E, Muller H, Rothenbacher D, Brenner H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 2009;49:802-808.
[CROSSREF] [PUBMED]
21. Ferrannini E, Balkau B, Coppack SW, Dekker JM, Mari A, Nolan J, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885-2892.
[CROSSREF] [PUBMED] [PDF]
22. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
[CROSSREF] [PUBMED]
23. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
[CROSSREF] [PUBMED]
24. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-1432.
[CROSSREF] [PUBMED]
25. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005;28:1757-1762.
[CROSSREF] [PUBMED]
26. Lee JH, Um MH, Park YK. The association of metabolic syndrome and serum γ-glutamyl transpeptidase: a 4-year cohort study of 3,698 Korean male workers. Clin Nutr Res 2013;2:67-75.
[CROSSREF] [PUBMED] [PMC]
27. Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med 2016;4:481
[CROSSREF] [PUBMED] [PMC]
28. Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int J Clin Pract 2015;69:136-144.
[CROSSREF] [PUBMED]
29. Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract 2012;66:692-698.
[CROSSREF] [PUBMED]
30. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med 2004;37:1018-1023.
[CROSSREF] [PUBMED]
31. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006;55:928-934.
[CROSSREF] [PUBMED]
32. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
[CROSSREF] [PUBMED]
33. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011;15:1911-1926.
[CROSSREF] [PUBMED]
34. Cannizzo B, Lujan A, Estrella N, Lembo C, Cruzado M, Castro C. Insulin resistance promotes early atherosclerosis via increased proinflammatory proteins and oxidative stress in fructose-fed ApoE-KO mice. Exp Diabetes Res 2012;2012:941304.
[CROSSREF] [PUBMED] [PMC] [PDF]
35. Venturini D, Simao AN, Scripes NA, Bahls LD, Melo PA, Belinetti FM, et al. Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome. Obesity (Silver Spring) 2012;20:2361-2366.
[CROSSREF] [PUBMED]
36. Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis 2015;6:109-120.
[CROSSREF] [PUBMED] [PMC]
37. Koenig G, Seneff S. Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers 2015;2015:818570.
[CROSSREF] [PUBMED] [PMC] [PDF]
38. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:936-944.
[CROSSREF] [PUBMED]
39. Sookoian S, Pirola CJ. NAFLD. Metabolic make-up of NASH: from fat and sugar to amino acids. Nat Rev Gastroenterol Hepatol 2014;11:205-207.
[CROSSREF] [PUBMED] [PDF]
40. Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramirez JC, Castro MG. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol 2012;24:805-810.
[CROSSREF] [PUBMED]
41. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005;37:246-251.
[CROSSREF] [PUBMED] [PDF]